
MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.
The trials used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint.